Agilent Technologies Inc. (NYSE:A) today announced that Yale University
has made a major purchase of Agilent bioanalytical systems to support
six research institutes it is establishing at its new West Campus.
Financial details were not disclosed.
Yale and Agilent officials also say they are discussing entering into a
scientific collaboration that would encompass integrative biology,
synthetic biology and quantitative proteomics to gain new insights into
disease mechanisms.
"Agilent provides sophisticated analytical instrumentation across a
broad spectrum of technologies,” said Christopher D. Incarvito, Ph.D.,
director of research technology at Yale’s West Campus. "This will be of
tremendous value to our chemistry, biology and genetics researchers.
This initial investment represents a substantial leap forward, and will
accelerate our ongoing and future research endeavors at West Campus.”
"Advancing our understanding of life-science systems requires
collaborative research across multiple platforms,” said Darlene Solomon,
Ph.D., Agilent chief technology officer. "Agilent solutions help
researchers integrate different types of biological data in pursuit of
medical breakthroughs, and the Yale group shares our vision.”
The purchase includes three nuclear magnetic resonance spectroscopy
systems; a 6120 single quadrupole and a 6490 triple quadrupole LC/MS
system; a 7890A GC/MS system; a BioCel 900 automation system; and
660-FTIR and 300-UV-Vis spectroscopy systems.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
electronics and communications. The company’s 18,700 employees serve
customers in more than 100 countries. Agilent had net revenues of $6.6
billion in fiscal 2011. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
